S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
The Day of Financial Reckoning Is Near (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
Stop Day Trading - More Here (Ad)pixel
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
Stop Day Trading - More Here (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
The Day of Financial Reckoning Is Near (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
Stop Day Trading - More Here (Ad)pixel
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
Stop Day Trading - More Here (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
The Day of Financial Reckoning Is Near (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
Stop Day Trading - More Here (Ad)pixel
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
Stop Day Trading - More Here (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
The Day of Financial Reckoning Is Near (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
Stop Day Trading - More Here (Ad)pixel
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
Stop Day Trading - More Here (Ad)pixel
NASDAQ:PRTK

Paratek Pharmaceuticals - PRTK Stock Forecast, Price & News

$2.79
+0.23 (+8.98%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.59
$2.83
50-Day Range
$1.80
$2.93
52-Week Range
$1.60
$5.72
Volume
362,471 shs
Average Volume
521,060 shs
Market Capitalization
$153.07 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$15.50

Paratek Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Strong Buy
3.50 Rating Score
Upside/​Downside
628.8% Upside
$20.33 Price Target
Short Interest
Bearish
10.19% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.98
Upright™ Environmental Score
News Sentiment
-0.14mentions of Paratek Pharmaceuticals in the last 14 days
Based on 15 Articles This Week
Insider Trading
Selling Shares
$306,477 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.92) to $0.48 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.86 out of 5 stars

Medical Sector

872nd out of 1,117 stocks

Pharmaceutical Preparations Industry

436th out of 550 stocks

PRTK stock logo

About Paratek Pharmaceuticals (NASDAQ:PRTK) Stock

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. In addition, it has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.

Paratek Pharmaceuticals Stock Performance

Shares of Paratek Pharmaceuticals stock traded up $0.23 during trading on Friday, hitting $2.79. 362,471 shares of the stock traded hands, compared to its average volume of 521,060. The stock has a market cap of $153.07 million, a P/E ratio of -1.65 and a beta of 1.52. Paratek Pharmaceuticals has a twelve month low of $1.60 and a twelve month high of $5.72. The company has a fifty day moving average price of $2.27 and a two-hundred day moving average price of $2.69.

Analysts Set New Price Targets

A number of equities research analysts have commented on PRTK shares. StockNews.com upgraded Paratek Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Thursday, May 5th. HC Wainwright decreased their price objective on Paratek Pharmaceuticals from $22.00 to $20.00 in a research report on Friday, May 6th.

Insider Activity

In other news, CEO Evan Loh sold 44,519 shares of Paratek Pharmaceuticals stock in a transaction dated Tuesday, August 9th. The stock was sold at an average price of $2.66, for a total transaction of $118,420.54. Following the completion of the sale, the chief executive officer now directly owns 1,257,742 shares in the company, valued at approximately $3,345,593.72. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In related news, Chairman Michael Bigham sold 28,637 shares of the firm's stock in a transaction that occurred on Tuesday, August 9th. The stock was sold at an average price of $2.66, for a total value of $76,174.42. Following the transaction, the chairman now directly owns 1,207,827 shares of the company's stock, valued at approximately $3,212,819.82. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Evan Loh sold 44,519 shares of Paratek Pharmaceuticals stock in a transaction that occurred on Tuesday, August 9th. The stock was sold at an average price of $2.66, for a total value of $118,420.54. Following the completion of the transaction, the chief executive officer now directly owns 1,257,742 shares in the company, valued at $3,345,593.72. The disclosure for this sale can be found here. Insiders sold a total of 115,217 shares of company stock worth $306,477 in the last three months. 8.00% of the stock is owned by insiders.

Receive PRTK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Paratek Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PRTK Stock News Headlines

Paratek Pharmaceuticals Q1 2022 Earnings Preview
See More Headlines
Receive PRTK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Paratek Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

PRTK Company Calendar

Last Earnings
11/08/2021
Today
8/12/2022
Next Earnings (Estimated)
11/14/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:PRTK
Previous Symbol
NASDAQ:TSPT
CUSIP
89354M10
Employees
207
Year Founded
1996

Price Target and Rating

Average Stock Price Forecast
$20.33
High Stock Price Forecast
$30.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+455.6%
Consensus Rating
Strong Buy
Rating Score (0-4)
3.50
Research Coverage
2 Analysts

Profitability

Net Income
$-59,080,000.00
Pretax Margin
-77.10%

Debt

Sales & Book Value

Annual Sales
$130.16 million
Book Value
($2.72) per share

Miscellaneous

Free Float
50,474,000
Market Cap
$153.07 million
Optionable
Optionable
Beta
1.52

Social Links















PRTK Stock - Frequently Asked Questions

Should I buy or sell Paratek Pharmaceuticals stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Paratek Pharmaceuticals in the last twelve months. There are currently 1 buy rating and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "strong buy" PRTK shares.
View PRTK analyst ratings
or view top-rated stocks.

What is Paratek Pharmaceuticals' stock price forecast for 2022?

2 Wall Street research analysts have issued 12-month price targets for Paratek Pharmaceuticals' shares. Their PRTK share price forecasts range from $11.00 to $30.00. On average, they expect the company's share price to reach $20.33 in the next twelve months. This suggests a possible upside of 626.2% from the stock's current price.
View analysts price targets for PRTK
or view top-rated stocks among Wall Street analysts.

How have PRTK shares performed in 2022?

Paratek Pharmaceuticals' stock was trading at $4.49 at the beginning of the year. Since then, PRTK stock has decreased by 37.6% and is now trading at $2.80.
View the best growth stocks for 2022 here
.

Are investors shorting Paratek Pharmaceuticals?

Paratek Pharmaceuticals saw a increase in short interest in July. As of July 31st, there was short interest totaling 4,170,000 shares, an increase of 17.1% from the July 15th total of 3,560,000 shares. Based on an average trading volume of 585,000 shares, the short-interest ratio is currently 7.1 days. Currently, 10.2% of the company's shares are sold short.
View Paratek Pharmaceuticals' Short Interest
.

When is Paratek Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our PRTK earnings forecast
.

How were Paratek Pharmaceuticals' earnings last quarter?

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) announced its earnings results on Monday, November, 8th. The specialty pharmaceutical company reported ($0.37) EPS for the quarter, topping analysts' consensus estimates of ($0.45) by $0.08. The specialty pharmaceutical company had revenue of $24.45 million for the quarter, compared to analysts' expectations of $22.98 million. During the same quarter in the prior year, the company posted ($0.46) EPS.

What guidance has Paratek Pharmaceuticals issued on next quarter's earnings?

Paratek Pharmaceuticals issued an update on its FY 2022 earnings guidance on Wednesday, August, 10th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $155.00 million-$170.00 million, compared to the consensus revenue estimate of $163.89 million.

What other stocks do shareholders of Paratek Pharmaceuticals own?

What is Paratek Pharmaceuticals' stock symbol?

Paratek Pharmaceuticals trades on the NASDAQ under the ticker symbol "PRTK."

Who are Paratek Pharmaceuticals' major shareholders?

Paratek Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include General American Investors Co. Inc. (3.22%), 1492 Capital Management LLC (0.89%), Pictet Asset Management SA (0.88%), Assenagon Asset Management S.A. (0.17%), Group One Trading L.P. (0.00%) and BNP Paribas Arbitrage SA (0.06%). Insiders that own company stock include Adam Woodrow, Evan Loh, Michael Bigham, Randall B Brenner and William M Haskel.
View institutional ownership trends
.

How do I buy shares of Paratek Pharmaceuticals?

Shares of PRTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Paratek Pharmaceuticals' stock price today?

One share of PRTK stock can currently be purchased for approximately $2.80.

How much money does Paratek Pharmaceuticals make?

Paratek Pharmaceuticals (NASDAQ:PRTK) has a market capitalization of $153.61 million and generates $130.16 million in revenue each year. The specialty pharmaceutical company earns $-59,080,000.00 in net income (profit) each year or ($1.69) on an earnings per share basis.

How many employees does Paratek Pharmaceuticals have?

The company employs 207 workers across the globe.

When was Paratek Pharmaceuticals founded?

Paratek Pharmaceuticals was founded in 1996.

How can I contact Paratek Pharmaceuticals?

Paratek Pharmaceuticals' mailing address is 75 PARK PLAZA, BOSTON MA, 02116. The official website for the company is www.paratekpharma.com. The specialty pharmaceutical company can be reached via phone at (617) 807-6600, via email at ir@paratekpharma.com, or via fax at 617-275-0039.

This page (NASDAQ:PRTK) was last updated on 8/13/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.